|
In partnership with |  |
|
& Paladin Power |
Good day, 360! |
Here are some of our top movers today. And don't forget to join Jeff Bishop in Market Masters at 11AM EST today for his live Market Rundown in Bullseye Trades🔥. Be the best prepared trader on the Street! |
|
FOCUS LIST🔎 |
PRTG - Up over 50% in the pre-market after announcing confirmatory preclinical results in Mesothelioma supporting first-in-human trial of PORT-7 |
CGON - Up over 40% in pre after best-in-disease durability data in BOND-003 cohort C and promising early signal in cohort P for Cretostimogene Grenadenorepvec at the American Urological Association annual meeting |
GNPX - Up over 14% in pre after signing exclusive technology license agreement with New York University Langone Health for the treatment of Mesothelioma |
|
*sponsored by CBDDistillery | Unwind Naturally with Enhanced Relief Gummies | | Feel the calm set in with these Enhanced Relief Gummies—crafted with 5mg THC + 75mg CBD for stress relief, reduced anxiety, and deep relaxation without the hangover. | Perfect for evenings when you need to truly unwind. Get 25% off your first order with code RLX25 and experience why this brand has over 48k 5-star reviews. | Shop & Relax Now |
|
|
|
HOTLIST🔥 |
PRTG - Up over 50% in the pre-market after announcing confirmatory preclinical results in Mesothelioma supporting first-in-human trial of PORT-7 |
Portage Biotech Inc. (PRTG) is a clinical stage immune-oncology company that engages in the research and develops pharmaceutical and biotechnology products. |
In the pre-market this morning, the company announced confirmatory preclinical efficacy data for PORT-7 (TT-4), a selective adenosine A2B receptor inhibitor. |
The new data in a murine mesothelioma model demonstrated single agent activity for PORT-7 that was superior to treatment with single agent anti-PD1 antibody. Moreover, the combination of PORT-7 and anti-PD1 was superior to treatment with either anti-PD1 or PORT-7 alone. Immunohistochemistry of the tumors revealed the formation of tertiary lymphoid structures in the mice receiving the combination. This indication of a favorable immune response was accompanied by increases in immune effector cells in mice treated with the combination. |
Portage is making preparations to commence a first-in-human clinical trial with PORT-7. |
Shares of PRTG traded up over 50% in the pre-market in reaction to the news. |
|
The $12.50 area acted as support in the pre-market and will be an important level to watch. |
Above it, targets to the upside are $14.20, $15 and then the pre-market high at $15.35. Beyond that, $15.82, $20 and $23 come into play. |
Below $12.50, targets to the downside are $12, $11, $10 and $9 and a gap fill at $8.45. |
|
CGON - Up over 40% in pre after best-in-disease durability data in BOND-003 cohort C and promising early signal in cohort P for Cretostimogene Grenadenorepvec at the American Urological Association annual meeting |
CG Oncology Inc. (CGON) is a late-stage clinical biopharmaceutical company that develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. |
Over the weekend, the company announced that cretostimogene grenadenorepvec monotherapy data was presented at the Practice-Changing, Paradigm-Shifting Clinical Trials in Urology Plenary Session at the 2025 American Urological Association (AUA) Annual Meeting, in Las Vegas, Nevada. |
Highlights include: |
- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – |
- 58.3% of patients showed durable complete responses by K-M at 24 months – |
- 97.3% of all treated patients remained free from progression to MIBC at 24 months– |
- 91.6% of responders remained cystectomy-free at 24 months – |
- No Grade 3 or greater treatment-related adverse events or deaths reported – |
- Strong initial Cohort P data reported 90.5% high-grade recurrence-free survival at 3 and 9 months by K-M – |
Shares of CGON traded up over 40% in the pre-market in reaction to the results. |
|
The first target for bulls is the pre-market high at $32.40. Beyond that, $34, $36, $38 and $40 come into play. |
Below $32.40, targets to the downside are $28, $27, $24 and then a gap fill at $22.37. |
|
*together with Paladin Power |
|
|
Paladin Scores 500% Sales Growth Thanks to Its Independent Energy System |
|
|
|
As the residential energy storage market surges toward $14B by 2027, it's evident that more Americans need reliable power. | Paladin Power delivers with a revolutionary total off-grid solution that powers everything (air conditioning, appliances, electric vehicles), all the time, in the smallest footprint on the market, and at the lowest cost per watt hour. Paladin offers up to 6x more inverter output than the competition's battery systems. | The big stat: Since launching in 2023, Paladin's growth has soared – hitting over $2M in sales in 2024, a 500% increase. And they only launched their product in 2023. | Want in? With over $1M already raised… | This popular deal is closing soon, on April 30th. | Invest now before the opportunity disappears. | Paladin Power Disclosure: This is a paid advertisement for Paladin Power's Regulation CF offering. Please read the offering circular and related risks. |
|
|
|
GNPX - Up over 14% in pre after signing exclusive technology license agreement with New York University Langone Health for the treatment of Mesothelioma |
Genprex Inc. (GNPX) is a clinical-stage gene therapy company that focuses on developing therapies for patients with cancer and diabetes. |
In the pre-market this morning, the company announced it has signed an exclusive patent license agreement with NYU Langone Health related to the drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid). |
The therapy is under investigation as a potential treatment for mesothelioma. The subject patent is co-owned by Genprex and NYU Langone Health, and the license provides Genprex with patent exclusivity. |
Shares of GNPX traded up over 14% in the pre-market in reaction to the news. |
|
The $0.30 area acted as support in the pre-market and will be an important level to watch. |
Above it, targets to the upside are $0.32, $0.34, $0.39 and then the pre-market high at $0.40. Beyond that, $0.4366 and $0.53 come into play. |
Below $0.30 targets to the downside are a gap to fill at $0.2846, $0.25 and then $0.22. |
|
MARKET NEWS 📰 |
|
|
Don't miss out on our MOBILE ALERTS! Some of these alerts have rocketed 🚀past the MOON 🌝. Text "RAGE" to 1-(888) 487-1534 📲. |
*Disclosure: By texting "RAGE" to 1-(888) 487-1534, you agree to receive promotional messages sent via an autodialer. You also agree to the terms of service and privacy policy. This agreement isn't a condition of any purchase. Message frequency varies. Message and data rates may apply. Reply STOP to opt out; HELP for more information. |
|
DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer | FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. | RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. | RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. | RagingBull.com, LLC shall be entitled to recover attorneys' fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys' fees, costs and disbursements in addition to any other relief to which it may be entitled. | *Sponsored Content: Paladin Power has paid RagingBull.com, LLC ("Raging Bull") fifteen thousand dollars to run advertisements enhancing public awareness of the company. RagingBull is not currently invested in the Company. RagingBull is also an affiliate for CB Distillery. If you purchase anything through a link in this email other than RagingBull (RB) services, you should assume that we have an affiliate relationship with the company providing the product that you purchase, and that we will be paid in some way. Further, we have been paid RB is not responsible for any content hosted on affiliate's sites and it is the affiliate's responsibility to ensure compliance with applicable laws. We recommend that you do your own independent research before purchasing anything. While we believe in the companies we form affiliate relationships with, please don't spend any money on these products unless you believe they will help you achieve your goals. | WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. |
|
|
Tidak ada komentar:
Posting Komentar